Skip to the page

Data / Drug companies / Dexmethylphenidate hydrochloride

Dexmethylphenidate hydrochloride: 17 companies and 114 products in the FDA NDC directory

Dexmethylphenidate hydrochloride is listed in the FDA National Drug Code Directory by 17 companies, with 114 products in commercial distribution. 87 of the products (76.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, extended release; tablet, and the newest product started marketing on October 1, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
17
Products
114
Generic (ANDA) products
87 (76.3%)
Application numbers
17
Controlled substance schedule
Schedule II
Routes
Oral
Brand names
Focalin XR, Focalin
openFDA record search
api.fda.gov

Companies that list dexmethylphenidate hydrochloride

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
Bryant Ranch Prepack13capsule, extended release; tabletGeneric drugs (ANDA)May 3, 2024
Sandoz Inc11capsule, extended release; tabletNew drug applications (NDA)May 31, 2005
Bryant Ranch Prepack10capsule, extended release; tabletGeneric drugs (ANDA)January 5, 2017
Camber Pharmaceuticals, Inc.8capsule, extended releaseGeneric drugs (ANDA)December 8, 2021
Granules Pharmaceuticals Inc.8capsule, extended releaseGeneric drugs (ANDA)December 1, 2020
Lannett Company, Inc.8capsule, extended releaseGeneric drugs (ANDA)October 9, 2018
Novartis Pharmaceuticals Corporation8capsule, extended releaseNew drug applications (NDA)May 31, 2005
Par Health USA, LLC8capsule, extended releaseGeneric drugs (ANDA)January 5, 2017
Sandoz Inc8capsule, extended releaseAuthorized generics (NDA)October 1, 2026
Teva Pharmaceuticals USA, Inc.8capsule, extended releaseGeneric drugs (ANDA)July 5, 2017
Amneal Pharmaceuticals of New York LLC7capsule, extended releaseGeneric drugs (ANDA)July 5, 2017
Ascend Laboratories, LLC3tabletGeneric drugs (ANDA)July 21, 2019
Cranbury Pharmaceuticals, LLC3tabletGeneric drugs (ANDA)November 30, 2001
KVK-Tech, Inc.3tabletGeneric drugs (ANDA)December 4, 2015
Lupin Pharmaceuticals,Inc.3tabletGeneric drugs (ANDA)December 4, 2015
Sun Pharmaceutical Industries, Inc.3tabletGeneric drugs (ANDA)September 26, 2013
Nivagen Pharmaceuticals, Inc.2tabletGeneric drugs (ANDA)May 3, 2024

Dosage forms

Dosage formProductsShare
Capsule, extended release8675.4%
Tablet2824.6%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)8776.3%
New drug applications (NDA)1916.7%
Authorized generics (NDA)87%

Pharmacologic classes

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.